In Brief: PathoGenesis Corp.
Executive Summary
PathoGenesis Corp.: Infectious disease R&D firm completes initial public offering of 3 mil. shares at $10 per share on Nov. 22, the Seattle-based firm announces. The company has granted its underwriter Prudential Securities the option to purchase an additional 450,000 shares of stock in a 30-day over-allotment clause. PathoGenesis' lead compound, TOBI for treatment of chronic lung infections in cystic fibrosis patients, began Phase III trials in the U.S. in July...